Your browser doesn't support javascript.
Management of immune checkpoint therapy for patients with cancer in the face of COVID-19.
Shen, Chen; Li, Qianru; Wei, Yongchang; Li, Yuting; Li, Jun; Tao, Juan.
  • Shen C; Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430022, China.
  • Li Q; Department of Immunology, School of Medicine, UConn Health, Farmington, CT 06032, USA.
  • Wei Y; Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430022, China.
  • Li Y; Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
  • Li J; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430022, China.
  • Tao J; Department of Dermatology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430014, China tjhappy@126.com goldcoindaniel@163.com.
J Immunother Cancer ; 8(2)2020 12.
Article in English | MEDLINE | ID: covidwho-971586
Semantic information from SemMedBD (by NLM)
1. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
2. Therapeutic procedure TREATS Chronic disease
Subject
Therapeutic procedure
Predicate
TREATS
Object
Chronic disease
3. Chronic disease PROCESS_OF Patients
Subject
Chronic disease
Predicate
PROCESS_OF
Object
Patients
4. Therapeutic procedure TREATS Patients
Subject
Therapeutic procedure
Predicate
TREATS
Object
Patients
5. Immune Checkpoint Inhibitors ADMINISTERED_TO Patients
Subject
Immune Checkpoint Inhibitors
Predicate
ADMINISTERED_TO
Object
Patients
6. Respiration Disorders PROCESS_OF Patients
Subject
Respiration Disorders
Predicate
PROCESS_OF
Object
Patients
7. Adverse effects PROCESS_OF Patients
Subject
Adverse effects
Predicate
PROCESS_OF
Object
Patients
8. Coronavirus Infections PROCESS_OF Patients
Subject
Coronavirus Infections
Predicate
PROCESS_OF
Object
Patients
9. Inflammation COEXISTS_WITH COVID-19
Subject
Inflammation
Predicate
COEXISTS_WITH
Object
COVID-19
10. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
11. NELFCD gene|NELFCD PRODUCES interleukin-6
Subject
NELFCD gene|NELFCD
Predicate
PRODUCES
Object
interleukin-6
12. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
13. Therapeutic procedure TREATS Chronic disease
Subject
Therapeutic procedure
Predicate
TREATS
Object
Chronic disease
14. Chronic disease PROCESS_OF Patients
Subject
Chronic disease
Predicate
PROCESS_OF
Object
Patients
15. Therapeutic procedure TREATS Patients
Subject
Therapeutic procedure
Predicate
TREATS
Object
Patients
16. Immune Checkpoint Inhibitors ADMINISTERED_TO Patients
Subject
Immune Checkpoint Inhibitors
Predicate
ADMINISTERED_TO
Object
Patients
17. Respiration Disorders PROCESS_OF Patients
Subject
Respiration Disorders
Predicate
PROCESS_OF
Object
Patients
18. Adverse effects PROCESS_OF Patients
Subject
Adverse effects
Predicate
PROCESS_OF
Object
Patients
19. Coronavirus Infections PROCESS_OF Patients
Subject
Coronavirus Infections
Predicate
PROCESS_OF
Object
Patients
20. Inflammation COEXISTS_WITH COVID-19
Subject
Inflammation
Predicate
COEXISTS_WITH
Object
COVID-19
21. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
22. NELFCD gene|NELFCD PRODUCES interleukin-6
Subject
NELFCD gene|NELFCD
Predicate
PRODUCES
Object
interleukin-6
ABSTRACT
The COVID-19 outbreak caused by SARS-CoV-2 challenges the medical system by interfering with routine therapies for many patients with chronic diseases. In patients with cancer receiving immune checkpoint inhibitors (ICIs), difficulties also arise from the incomplete understanding of the intricate interplay between their routine treatment and pathogenesis of the novel virus. By referring to previous ICI-based investigations, we speculate that ICIs themselves are not linked to high-infection risks of respiratory diseases or inflammation-related adverse effects in patients with cancer. Moreover, ICI treatment may even enhance coronavirus clearance in some patients with malignant tumor by boosting antiviral T-cell responsiveness. However, the 'explosive' inflammation during COVID-19 in some ICI-treated patients with cancer was illustrated as exuberant immunopathological damage or even death. In case of the COVID-19 immunopathogenesis fueled by ICIs, we propose a regular monitor of pathogenic T-cell subsets and their exhaustion marker expression (eg, Th17 and interleukin (IL)-6-producing Th1 subsets with surface programmed death 1 expression) to guide the usage of ICI. Here we aimed to address these considerations, based on available literature and experience from our practice, that may assist with the decision-making of ICI administration during the pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Antineoplastic Agents, Immunological / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Neoplasms Subject: Antineoplastic Agents, Immunological / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Neoplasms Language: English Clinical aspect: Etiology / Therapy Year: 2020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Antineoplastic Agents, Immunological / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Neoplasms Subject: Antineoplastic Agents, Immunological / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / Neoplasms Language: English Clinical aspect: Etiology / Therapy Year: 2020
...